NewsMedical speaks with Prof. Martin Cowie, Interim Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca, and Dr. Lisa Anderson, Heart Failure Specialist and Consultant Cardiologist at St George's Hospital, London, UK.
They discuss findings from the REVOLUTION HF and OverTTuRe studies, emphasizing the need for early diagnosis and intervention to improve patient outcomes and reduce healthcare costs. Prof. Cowie: I am the Interim Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca.
Previously, I served as the Chair of the Digital Health Committee of the European Society of Cardiology (2019-2022) and from 2016-2020 was a Non-Executive Director of the National Institute for Health and Care Excellence (NICE) in the UK. I was also a Consultant Cardiologist at the Royal Brompton Hospital, London and led the multi-professional heart failure service from 2001 until 2022. As a cardiologist, I’ve seen first-hand the devastating impact of complex cardiovascular disease, including heart failure, and I’ve been privileged to help thousands of people manage their health issues during my time in clinical practice.
Dr. Anderson: I am a Heart Failure Specialist and Consultant Cardiologist at St George’s Hospital, London, UK, and currently chair the British Society for Heart Failure, the NHS England Heart Failure Expert Advisory Group and .